Literature DB >> 11848914

Partially Modified Retro-Inverso Peptides: Development, Synthesis, and Conformational Behavior.

Matthew David Fletcher1, Malcolm M. Campbell.   

Abstract

Year:  1998        PMID： 11848914     DOI： 10.1021/cr970468t

Source DB:  PubMed          Journal:  Chem Rev        ISSN： 0009-2665            Impact factor:   60.622


× No keyword cloud information.
  20 in total

1.  Cyclic, linear, cycloretro-isomer, and cycloretro-inverso peptides derived from the C-terminal sequence of bradykinin as substrates or inhibitors of serine and cysteine proteases.

Authors:  Aurelio Resende Lima; Luiz Juliano; Maria Aparecida Juliano
Journal:  Protein J       Date:  2004-05       Impact factor: 2.371

Review 2.  A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.

Authors:  Pravin T P Kaumaya
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Force-field parametrization of retro-inverso modified residues: development of torsional and electrostatic parameters.

Authors:  David Curcó; Francisco Rodríguez-Ropero; Carlos Alemán
Journal:  J Comput Aided Mol Des       Date:  2006-04-19       Impact factor: 3.686

4.  Integrating the intrinsic conformational preferences of noncoded α-amino acids modified at the peptide bond into the noncoded amino acids database.

Authors:  Guillem Revilla-López; Francisco Rodríguez-Ropero; David Curcó; Juan Torras; M Isabel Calaza; David Zanuy; Ana I Jiménez; Carlos Cativiela; Ruth Nussinov; Carlos Alemán
Journal:  Proteins       Date:  2011-04-12

5.  Prophylactic and therapeutic suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor.

Authors:  Naoki Kobayashi; Paul Kiptoo; Hitomi Kobayashi; Rahmawati Ridwan; Stefan Brocke; Teruna J Siahaan
Journal:  Clin Immunol       Date:  2008-08-03       Impact factor: 3.969

6.  A multicomponent approach to the synthesis of 1,3-dicarbonylic compounds.

Authors:  Ana G Neo; Rosa M Carrillo; Jose Delgado; Stefano Marcaccini; Carlos F Marcos
Journal:  Mol Divers       Date:  2010-09-03       Impact factor: 2.943

Review 7.  Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.

Authors:  Pravin T P Kaumaya; Kevin Chu Foy
Journal:  Future Oncol       Date:  2012-08       Impact factor: 3.404

8.  Excipients for the lyoprotection of MAPKAP kinase 2 inhibitory peptide nano-polyplexes.

Authors:  Alvin J Mukalel; Brian C Evans; Kameron V Kilchrist; Eric A Dailing; Benjamin Burdette; Joyce Cheung-Flynn; Colleen M Brophy; Craig L Duvall
Journal:  J Control Release       Date:  2018-04-27       Impact factor: 9.776

9.  Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo.

Authors:  Kevin C Foy; Zhenzhen Liu; Gary Phillips; Megan Miller; Pravin T P Kaumaya
Journal:  J Biol Chem       Date:  2011-02-16       Impact factor: 5.157

10.  Enzymatic self-assembly of an immunoreceptor tyrosine-based inhibitory motif (ITIM).

Authors:  Natsuko Yamagata; Xiaoyi Chen; Jie Zhou; Jie Li; Xuewen Du; Bing Xu
Journal:  Org Biomol Chem       Date:  2017-07-04       Impact factor: 3.876
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.